NRXP NRX Pharmaceuticals Inc

$NRXP Will close around $2.50. Bought another 35K shares today. This stock will reach $15-20 within 12 months. After reading through the comments here, I have to say: if investing brings out this much hatred, racism, and finger-pointing, perhaps investing isn't for you. It's embarrassing to watch grown adults lose all perspective, throw emotional tantrums, and blame JJ for everything, despite the fact that he was instrumental in bringing KetaFREE to market. Let's be clear: investing comes with risks. Not every decision will go your way, and not every outcome will meet your expectations. That's part of the game. You can question management, challenge decisions, and hold people accountable without resorting to personal attacks, racism, or childish behavior. If you can't handle volatility, uncertainty, or the possibility of being wrong, you need to reconsider whether the stock market is the right place for you.

$NRXP Buy in early cos very soon it will be TOTALLY OUT OF REACH.. See you all at $50+…. I am making this money

$NRXP Buy time. Filled 2.13/14. Reddist candle on the chart - generally they snap back. Target into $3

$NRXP Approval... we are in the FDA’s Orange Book. Hearty congratulations to the bulls. Very good work by you and your team! Bravo!

$NRXP Until now, the CEO and management have conveniently hidden behind the FDA approval process to excuse their lack of progress. Now that approval has been granted, it's time to deliver real results instead of recycling the same promises and optimistic projections. Long-term shareholders deserve actual revenue, commercial success, and shareholder value—not endless dilution and disappointment. Management must finally justify its six-figure salaries and bonuses through performance, not press releases. The time for excuses is over. Less talk, more execution.

$NRXP Yeah. Finally, something important has been accomplished! Congratulations to the company, and especially congratulations to everyone who is hodling this stock since the BRPA days. Finally, a major success. You deserve it, guys and gals! I'm hoping for an announcement during today's call regarding a LOI or MOU for a large shipment of Ketafree (or whatever the product ends up being called). Then we might see how much of the battle against shorties is left. Anything below $5 today would be disappointing in my opinion. But as usual, even a "sell-the-news" reaction would not really surprise me. We have seen it often enough. Let's see what the day brings. Any new offering would also be disappointing. Company shouldn't squander any potential momentum! GLTA. Happy trading today.

$NRXP No DILUTION No DILUTION No DILUTION No DILUTION Dr. Javitt Dr. Javitt Dr. Javitt well done. Been believing for a long time. About time, its been 6 long years since the Spac, money tied up with NRXP. Cant sell as would loose to much. You get more money by issuing shares, we cant. For once Dont dilute in the next 6 months, you got money from the goverment, you got CASH until middle of next year, you will be pulling the cash in for the sale of Ketamin. No DILUTION No DILUTION No DILUTION No DILUTION

$NRXP Get ready for a Gamestop part 2 tomorrow....shorts are screwed with the early approval we going past 10

$NRXP After this approval FDA has all reasons to phase out or ban any other ketamine which is not preservative-free. IMHO shorts attack is unique market opportunity. Do your own DD. GLA....

$NRXP thank you to whoever posted this on penny stock on reddit about this company yesterday.

$NRXP Huge accomplishment on the approval. Well done to Dr. Javitt and the team and hope for future patients. The near-term roadmap appears fairly clear: growth, execution, and minimal dilution can be mutually reinforcing rather than competing objectives. Achieving a stronger share price makes expansion funding more efficient, requiring fewer new shares while helping preserve value associated with the Hope spin-off. From a shareholder perspective, that's arguably the most efficient path forward. November 16 earnings call should provide important insight into how Dr. Javitt and the team plan to balance execution, financing needs, and long-term value creation. Execution is critical, but so is capital discipline. Excessive dilution risks undermining the very shareholder value that successful execution is intended to create. Let’s go.

$NRXP Your disastrous presentation turned a regulatory triumph into a sell-off. Shareholders deserve transparency and hard numbers, not silence. What's next?

$NRXP This stock has to go up. They have product that is already made, ready to be sold. No cost or time to produce. Channels in place to distribute. They have a safe product that is currently backlogged. Glenn Tyson has a proven track record and is Chief Commerical officer. As of June they had 1 year cash runway. I hope next week this hits 5. One PO come in then tonight but I think possible dilution risk at that point. Thoughts? Am I off here?

$NRXP welcome new bagholders, some of us have been here 4 years, the sun will rise tomorrow, pray your wife dont find out and forget about that motorcycle purchase you was going to get with your profits. Our day is coming, just not today.

$NRXP .....Sales 101 'Ketamine for injection has been on the national drug shortage list since February 2018. According to the American Society of Health-System Pharmacists, all 6 ketamine manufacturers have at least 1 form of product back ordered, intermittent & some manufacturers have recently discontinued production.' In 2025, ketamine demand grew 17%. The problem has been supply. Every group purchasing organization & every pharmacist we spoke with named supply of ketamine as a top concern. Health systems scored supply shortages at a score of 4.6/5. It was their top pain point. Those buyers told us that they will switch for reliable supply and simpler, safer preparation. We identified no customer allegiance to current offshore suppliers of ketamine. And right now, U.S. hospitals reaching out to compounding pharmacies to buy ketamine in emergency situations because they can't get it through the legitimate pharmaceutical supply chain. So we intend to end that problem. '

$NRXP IMO, ehoever holds NRXP 18 million in warrants is shorting this down, then selling notes to cover. If you dont hear from me again its because I got banned, wont be the first time and I’m out of email accounts to start another

$NRXP Listened to the CC. And as always, going to hinge on how sales go. Clear they have a plan for upticking sales, so just have to see how it goes. 43 Mil shares outstanding, Yahoo showing almost 10 Mil shorted, lot of covering to take place, but doesn't help todays market is puking itself as the AI hype BS falls apart. So with a market cap of around $85 Million at $2.16 a share? Still holding onto my target price of $8-10 once sales commence. Only be a market cap of around $320 - 450 Mil... So, going to have to be a bit more patient to let this now 'earn' its way forward. And then see what else they can finally move thru the pipeline towards being a source of revenue. PS: see a lot of a-holes are on the board today. Go figure..

$NRXP While the FDA approval of KETAFREE ANDA is a major regulatory milestone, the structure of today's call left the market deeply disappointed. Focusing primarily on pharmaceutical background while deferring concrete financial guidance gave short sellers an immediate opportunity to depress the share price. To restore market confidence, I strongly urge management to provide clear, timely updates on: 1. The official NDA submission timeline for NRX-100. 2. Initial purchase orders (POs) and concrete commercial revenue guidance.

$NRXP - Remember Metric Estimate Average 12-month target $35.00 - TipRanks Average 12-month target - StockAnalysis $38.50 Average 12-month target — MarketBeat

$NRXP easy double. Probably going $12+ short term $GCTK I’m holding. The delist will be reversed on appeal and the company has many new revenue contracts for its ai service to be announced